Novartis announced plans to establish a flagship manufacturing hub in North Carolina as part of a $23 billion U.S. infrastructure investment, adding biologics, sterile packaging, and solid‑dose capabilities. The company said the expansion will enable end‑to‑end production of key medicines domestically and support cell‑and‑gene, radioligand, and xRNA therapies across U.S. sites. Novartis detailed construction of new facilities in Durham and Morrisville, capacity expansions at existing campuses, and plans to create roughly 700 direct jobs plus thousands of indirect positions by 2030. CEO Vas Narasimhan framed the move as strengthening supply‑chain resilience and ensuring local manufacturing for advanced technologies. The investment signals continued onshoring trends among large pharma, driven by strategic supply security, regulatory considerations, and demand for biologics and complex modalities that require localized manufacturing expertise.